Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Featured Stories

GSK Drops Out Of Auction For Pfizer's Consumer Health Unit

The acquisition of Pfizer's consumer health business, which includes big named products such as Advil painkillers and Centrum multivitamins, has proven too big and too costly for GSK investors to stomach.

M & A Deals Consumer

CHMP Nod For Ipsen's Mainstay Cancer Drug Cabometyx In First-Line RCC

The EMA's drug assessment committee, the CHMP, has given Ipsen's Cabometyx a positive recommendation for use in first-line kidney cancer, a label extension that will add more weight to the company's standing as a cancer specialist.

Policy & Regulation Cancer Approvals

Novartis' Siponimod Heads Towards Regulators As Experts Question Its Effects

As Novartis prepares its imminent US filing for its Gilenya follow-up siponimod some experts are underwhelmed by its pivotal EXPAND study.

Clinical Trials Companies Research & Development

 Recent Tweets from Scrip


Commercial Explore this Topic

Set Alert for Commercial

Hyperkalemia Market Hots Up In EU with Okay for AZ's Lokelma

Rival Vifor Pharma has predicted blockbuster status for Veltassa and AstraZeneca expects the same for its just-approved oral potassium-removing agent, hoping that Lokelma's faster onset of action will help it win the fight for market share in hyperkalemia.

Approvals Europe Policy & Regulation

Zelluna Immunotherapy Seeks TCR Share Of Voice

Immunotherapy is currently one of the hottest areas in biotech, so differentiating from the crowd is a major challenge for startups in the space. Zelluna Immunotherapy CEO Miguel Forte explains to Scrip how his company intends to get share of voice in the busy TCR landscape.

Commercial ImmunoOncology StartUps and SMEs

Morphosys Seeks US Listing To Cement Corporate Developments

German biotech Morphosys has filed an F-1 registration statement with the US Securities & Exchange Commission to list the ADSs on the Nasdaq Global Market to raise its profile among US investors and raise up to $150m. Funds will primarily be used to support the company’s ambitions to commercialize MOR208 in the US.

Financing Commercial

Finance Watch: The Curious Case Of Proteostasis' Short Attack

Proteostasis planned to raise cash this week, but scrapped the offering after an investor that shorted the stock published a scathing report. Also, Arena raised more than $350m in an offering after its positive Phase II etrasimod data, and venture capital flows to biopharma firms with big ideas.

Financing Business Strategies

Perfect Pitch: Rheos Raises $60m To Tune Immune Cells In Autoimmune Diseases

The Third Rock Ventures-funded start-up Rheos Medicines raised a $60m Series A round to study immune cell metabolism for drug targets that allow the company to fine-tune the immune system in autoimmune and inflammatory diseases, as well as cancer.

Financing Immune Disorders

Alnylam and Regeneron Plan 50/50 Gene R&D Pact To Find NASH RNAi Drugs

Duo to equally share development costs and profits from any candidates emerging from their RNAi discovery pact.

Commercial Companies

Crescendo Aims To Increase IO Share Of Voice With Humabody Platform

The Immuno-oncology space is a crowded and consequently represents a big challenge for small biotechs to get share of voice. Crescendo Biologics CEO Peter Pack took time off from his busy partnering schedule at BIO-Europe Spring 2018 to outline to Scrip how the company's Humabody platform is being used to develop both in-house and partnered opportunities.


ImmunoOncology Platform Technologies

Ilumya Becomes Sun's New Branded Specialty Drug Pillar

FDA approved Ilumya for moderate to severe plaque psoriasis, furthering the competitive dynamics in the crowded psoriasis market, and establishing the biologic as a major pillar of Sun's new branded specialty drug business.

Approvals Dermatology

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

GSK Secures EU & Japanese Approvals For Shingrix

Hot on the heels of the FDA approval, GlaxoSmithKline has received the green light for its shingles vaccine Shingrix from both the EU Commission and the Japanese Ministry of Health, Labour and Welfare but it is remaining tightlipped about its commercialization plans.

Approvals Vaccines Infectious Diseases

Drug Pricing: A Game Of Chutes & Ladders

The US drug pricing policy environment is facing changes. Much of the action, whether Congressional or regulatory, is good for industry – but there have been a few setbacks and more may come.

Market Access Pricing Debate

The Ups and Downs Of US Drug Pricing Policy

If 2017 was the year of talk (tweets) on prescription drug pricing policy, 2018 is shaping up to be the year of action.

Pricing Debate Market Access

Seattle Genetics Says Adcetris Sets New Standard In Frontline Lymphoma

The market for a new FDA-approved indication in frontline classical Hodgkin lymphoma could be worth $650m to $750m, some analysts say.

Approvals Cancer

Research & Development Explore this Topic

Set Alert for Research & Development

Tech Transfer Roundup: ProQR Partners With Foundation Fighting Blindness On Rare Vision-Loss Disorder

Galderma unveils seven-year partnership with Mount Sinai and Northwestern in atopic dermatitis. Beacon/Takeda and Zealand/UniQuest tie-ups both address gastrointestinal diseases.

Deals Business Strategies Research & Development

Weak Rova-T Data May Imperil AbbVie's Larger Cancer Ambitions

Analysts already were skeptical about AbbVie's $5bn peak earnings projections for the ADC, but now some wonder if so-so data in third-line small cell lung cancer threaten Rova-T's viability for approval.

Clinical Trials Cancer

Celgene Further Commits To Neuroscience With Prothena Pact

It is a risky business but the biotech major is paying $150m upfront, and potentially hundreds of millions of dollars more, to work with Prothena and develop therapies targeted at proteins implicated in highly challenging neurodegenerative diseases such as Alzheimer's and ALS.

Neurology Deals

Seattle Genetics Says Adcetris Sets New Standard In Frontline Lymphoma

The market for a new FDA-approved indication in frontline classical Hodgkin lymphoma could be worth $650m to $750m, some analysts say.

Approvals Cancer